Results provide a mechanistic explanation of why early loss of p53 signaling is frequently observed in UC-associated ...
Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...
A team of researchers led by Kimberly Hartl, a graduate student at the Berlin Institute for Medical Systems Biology of the ...
Researchers have elucidated the role of the p53 gene in ulcerative colitis. The study suggests a potential new drug target to stop disease progression to cancer.
New research highlights a pivotal role for the p53 gene in ulcerative colitis progression, offering a potential therapeutic ...
News Medical on MSN2d
P53 Mutation: A Key Player in Cancer Risk for Ulcerative Colitis PatientsResearchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated ...
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...
clinicaltrialsarena on MSN12d
Innovent’s trial of picankibart for ulcerative colitis meets primary endpointInnovent Biologics has reported that its trial of picankibart (IBI112) in Chinese patients with ulcerative colitis met the ...
Abdominal pain, diarrhea, and debilitating fatigue define the daily lives of millions of people worldwide who suffer from ...
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback